Tekmira Pharmaceuticals Corporation  

(Public, NASDAQ:TKMR)   Watch this stock  
Find more results for TKMR
16.68
-0.26 (-1.53%)
Oct 31 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 16.50 - 17.50
52 week 7.17 - 31.48
Open 17.50
Vol / Avg. 994,105.00/5.80M
Mkt cap 374.48M
P/E     -
Div/yield     -
EPS -1.57
Shares 22.07M
Beta 1.24
Inst. own     -
Nov 6, 2014
Q3 2014 Tekmira Pharmaceuticals Corp Earnings Call - 5:00PM EST - Add to calendar
Nov 6, 2014
Q3 2014 Tekmira Pharmaceuticals Corp Earnings Release - 4:00PM EST - Add to calendar
Oct 7, 2014
Tekmira Pharmaceuticals Corp at BIO Investor Forum
Oct 1, 2014
Tekmira Pharmaceuticals Corp at Leerink Rare Disease Roundtable
Sep 22, 2014
Tekmira Pharmaceuticals Corp at Maxim Group's Institutional NYC BioDefense Mini-Conference
Aug 13, 2014
Q2 2014 Tekmira Pharmaceuticals Corp Earnings Call
Aug 13, 2014
Q2 2014 Tekmira Pharmaceuticals Corp Earnings Release
More events from DailyFinance »    

Address

Suite 100, 8900 Glenlyon Parkway
BURNABY, BC V5J 5J8
Canada
+1-604-4193200 (Phone)
+1-604-4193201 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Tekmira Pharmaceuticals Corporation is a biopharmaceutical company focused on advancing ribonucleic acid (RNA) interference (RNAi) therapeutics and providing its lipid nanoparticle (LNP) delivery technology to pharmaceutical partners. On March 1, 2012, it announced that the Company had secured a license from Alnylam to develop TKMALDH2, an RNAi therapeutic that utilizes Tekmira's LNP for the treatment of Alcohol Dependence (AD). Its lead oncology product candidate, TKM-PLK1, targets PLK1, a protein involved in tumor cell proliferation and a validated oncology target. On February 8, 2012, it announced that Phase I clinical trial for TKM-Ebola had been initiated. The Phase 1 TKM-Ebola clinical trial is a placebo-controlled, single-blind, single-ascending dose study with additional multiple-ascending dose cohorts in healthy human volunteers. In the field of RNAi therapeutics, the Company has licensed its LNP delivery technology to Alnylam Pharmaceuticals, Inc. and Merck & Co., Inc.

Officers and directors

Daniel L. Kisner M.D. Independent Chairman of the Board
Age: 67
Bio & Compensation  - Reuters
Mark J. Murray Ph.D. President, Chief Executive Officer, Director
Age: 65
Bio & Compensation  - Reuters
Bruce G. Cousins Chief Financial Officer, Executive Vice President
Age: 53
Bio & Compensation  - Reuters
Ian MacLachlan Ph.D. Executive Vice President, Chief Technical Officer
Age: 50
Bio & Compensation  - Reuters
Michael J. Abrams Ph.D. Executive Vice President and Chief Discovery Officer
Age: 57
Bio & Compensation  - Reuters
Mark Kowalski M.D., Ph.D. Chief Medical Officer, Senior Vice President
Age: 59
Bio & Compensation  - Reuters
Peter Lutwyche Ph.D. Senior Vice President - Pharmaceutical Development
Bio & Compensation  - Reuters
R. Hector MacKay-Dunn QC Corporate Secretary
Bio & Compensation  - Reuters
Peggy V. Phillips Director
Age: 60
Bio & Compensation  - Reuters
Donald G. Jewell Independent Director
Age: 60
Bio & Compensation  - Reuters